- Home
- Equipment
- usa new jersey
- therapies and technologies in clinical
Refine by
Therapies And Technologies In Clinical Equipment Supplied In Usa New Jersey
5 equipment items found
Manufactured by:Integra LifeSciences based inPrinceton, NEW JERSEY (USA)
Providing the power, performance and protection of silver for your wound management ...
Manufactured by:Integra LifeSciences based inPrinceton, NEW JERSEY (USA)
Manufactured using a proprietary super-absorbent polymer (SAP) technology, XTRASORB® HCS, Foam and “Classic” dressings outperform other standard moist wound healing dressings on multiple attributes. The XTRASORB family of first-line moist wound healing dressings are designed to exceed the performance of the market-leading brands, making care easier for clinicians and ...
Manufactured by:Origin, Inc based inPrinceton, NEW JERSEY (USA)
IonoStim is our most advanced Program, the focus of which is wound healing. We are leveraging NO’s potent antimicrobial activity along with its ability to stimulate the body’s natural healing mechanisms. Skin is the largest organ in the human body, and so it is not surprising that costs associated with treating wounds account for a large proportion of global healthcare ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indications: BENDEKA® is indicated for the treatment of patients with Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing ...